Do You Have to Take Wegovy Forever? What the Evidence Shows

Nothing in the FDA-approved label requires taking Wegovy for life. The label describes Wegovy as a medicine to “reduce excess body weight and maintain weight reduction long term,” and it sets no stop date or maximum duration ^[1]. Zepbound’s label uses the same long-term maintenance wording ^[2]. Guidance issued in 2026 by the Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition gives a strong recommendation to continue obesity medication during weight maintenance ^[3]. The reason is simple: in randomized withdrawal trials, people who stopped the drug regained most of their lost weight within a year, while people who continued kept it off or lost more ^[4][5].

Between staying on the full dose indefinitely and quitting outright, there are labeled lower maintenance doses, an oral form of Wegovy, and maintenance strategies now being studied. What there is not, yet, is a tested way to taper off that has been shown to prevent regain ^[25][29]. Every dosing decision belongs with a prescriber; the details below describe what the labels and the research say, not what any one person should take.

What do the Wegovy and Zepbound labels say about dosing and maintenance?

The Wegovy injection label tells patients to start at 0.25 mg once weekly for 4 weeks, then follow an escalation schedule that steps up every 4 weeks toward the maintenance dose. The usual recommended maintenance dosage of the injection is 2.4 mg once weekly. For weight reduction in adults, the label lists the maintenance dosage as either 1.7 mg or 2.4 mg (recommended) once weekly, and it says to consider treatment response and tolerability when selecting the maintenance dosage ^[1].

Wegovy also comes as a tablet. The recommended maintenance dosage of the tablets is 25 mg once daily. If a patient does not tolerate the 25 mg daily maintenance dosage, the label says to consider switching to the 1.7 mg once-weekly injection ^[1].

For Zepbound, the recommended starting dosage is 2.5 mg once weekly for 4 weeks, and the label states that 2.5 mg is for initiation only and is not approved as a maintenance dosage. For weight reduction and long-term maintenance, the recommended maintenance dosage is 5 mg, 10 mg, or 15 mg once weekly, with 15 mg the maximum. The label also says that if a patient does not tolerate a maintenance dosage, a lower maintenance dosage should be considered ^[2].

Why does obesity medicine treat this as a chronic therapy?

The 2026 joint guidance statement from TOS, OMA, and OAC was built using the GRADE method by a multidisciplinary panel that included patient representatives as well as obesity care providers. It issued strong recommendations for semaglutide and tirzepatide based on moderate-certainty evidence, and it gave continuing obesity medications during weight maintenance a strong recommendation. The statement describes obesity as a chronic, often progressive disease that needs comprehensive, long-term, person-centered care ^[3].

A 2026 expert panel of US and Chinese clinicians, writing in Obesity, went further and reached a consensus that pharmacotherapy is lifelong once initiated, because stopping consistently leads to weight regain and loss of metabolic benefit. The same panel noted that a weight plateau should be expected and read as evidence of maximal effectiveness rather than medication failure. That position is expert opinion, not graded evidence ^[28].

What happens to weight when semaglutide is stopped?

The clearest answer comes from the STEP 4 trial. A total of 803 adults with overweight or obesity, none with diabetes, completed a 20-week run-in on semaglutide 2.4 mg once weekly, losing an average of 10.6% of body weight. They were then randomized to either continue semaglutide or switch to placebo for 48 more weeks, with both groups receiving lifestyle counseling ^[4].

From week 20 to week 68, the group that continued semaglutide lost another 7.9% of body weight on average, while the group switched to placebo regained 6.9% — a difference of 14.8 percentage points. Waist circumference fell 6.4 cm with continued treatment and rose 3.3 cm with placebo. Systolic blood pressure rose 0.5 mm Hg in the semaglutide group and 4.4 mm Hg in the placebo group, and physical functioning scores on the SF-36 survey improved 1.0 points with semaglutide and worsened 1.5 points with placebo ^[4].

What happens when tirzepatide is stopped?

The tirzepatide version of that experiment is SURMOUNT-4. Researchers enrolled 783 adults with obesity, or overweight with a weight-related complication, and gave all of them open-label tirzepatide at the maximum tolerated dose (10 or 15 mg weekly) for 36 weeks. Participants lost an average of 20.9% of body weight. Then 670 of them were randomized to continue tirzepatide or switch to placebo for 52 weeks ^[5].

From week 36 to week 88, the tirzepatide group lost another 5.5% of body weight, while the placebo group regained 14.0% — a difference of 19.4 percentage points. Among those who continued, 89.5% kept at least 80% of the weight they had lost during the lead-in, compared with 16.6% of those who stopped. Counting from the very start of the study to week 88, total weight loss averaged 25.3% with continued tirzepatide versus 9.9% after withdrawal ^[5].

How fast does weight come back after stopping?

Regain after stopping a GLP-1 tends to be front-loaded: a large share of it happens in the early months after cessation. A 2026 review describes the mechanisms behind this pattern, including the return of appetite once the drug’s effect is gone, compensatory rises in orexigenic hormones such as ghrelin, and reduced energy expenditure in the weight-reduced state. The review notes that abrupt discontinuation can create a mismatch between a renewed biological drive to regain weight and the sudden loss of pharmacological appetite suppression ^[25].

The STEP 4 and SURMOUNT-4 numbers above fit that pattern: most of the difference between continuing and stopping built up within roughly a year of withdrawal ^[4][5].

How long have people actually taken semaglutide 2.4 mg in trials?

The longest randomized exposure reported in these sources is the SELECT trial, which enrolled 17,604 adults age 45 and older with a BMI of 27 or higher and established cardiovascular disease but no diabetes, across 804 sites in 41 countries. Participants were treated for a mean of 34.2 months and followed for a mean of 39.8 months ^[7].

In SELECT, weight loss with semaglutide continued over 65 weeks and was sustained for up to 4 years. At week 208, semaglutide was associated with a mean weight reduction of 10.2% versus 1.5% with placebo, and a waist circumference reduction of 7.7 cm versus 1.3 cm ^[8]. STEP 5 added two-year data in a different population: 304 adults treated for 104 weeks lost an average of 15.2% of body weight with semaglutide 2.4 mg versus 2.6% with placebo, and 77.1% versus 34.4% achieved at least 5% weight loss ^[9]. Beyond about four years, no randomized data appear in these sources ^[8].

Is it safe to take a GLP-1 for years?

SELECT is the main safety evidence for long-term use, covering nearly four years of treatment in a large population. Serious adverse events were less common with semaglutide than placebo: 33.4% versus 36.4%, a gap driven mainly by cardiac disorders (11.5% vs 13.5%) and infections (7.1% vs 8.4%) ^[7][10].

Adverse events leading to permanent discontinuation were more common with semaglutide, 16.6% versus 8.2%, and that gap was driven by gastrointestinal disorders (10.0% vs 2.0%). Discontinuation because of serious adverse events was similar between groups, 3.6% versus 4.1% ^[7][10].

The SELECT safety analysis found no between-group difference in serious psychiatric disorders, in suicide or self-injury events (0.11% in both groups), in acute pancreatitis, or in malignant neoplasms. Gallbladder-related disorders were more frequent with semaglutide (2.8% vs 2.3%), mainly cholelithiasis (gallstones) ^[10]. Serious adverse event rates were lower with semaglutide in every BMI category, while discontinuations rose as BMI class decreased ^[8].

One limit on reading SELECT as evidence for everyone: the population was mostly male (72.3%), with a mean age of 61.6 and existing heart disease, so the results may not generalize to younger, healthier, or more female populations ^[10].

What are the options between full dose indefinitely and stopping outright?

The labels themselves describe lower maintenance doses: Wegovy injection lists 1.7 mg or 2.4 mg for adult weight reduction, and Zepbound lists 5 mg, 10 mg, or 15 mg, with the label directing prescribers to consider a lower maintenance dosage when one is not tolerated ^[1][2]. Those are labeled options, not suggestions for any particular reader.

There is also one-year randomized evidence for switching from an injectable to a daily oral GLP-1. In the ATTAIN-MAINTAIN trial, adults who had finished the SURMOUNT-5 study on tirzepatide (205 people) or semaglutide (171 people) were randomized to the oral drug orforglipron or placebo for 52 weeks. Among those who had plateaued on tirzepatide, participants kept an estimated 74.7% of their weight loss on orforglipron versus 49.2% on placebo. In the semaglutide cohort, the figures were 79.3% versus 37.6% ^[12]. The trial’s own stated limitations are that there was no arm continuing the injectable, and it lasted only one year — so it does not show orforglipron is equal to staying on the injection ^[12].

Two 2026 papers, both commentary rather than guidelines, sketch a wider menu. A framework in Diabetes, Obesity and Metabolism proposes an injectable induction phase followed by maintenance through a lower-dose injectable, a switch to an oral GLP-1, or lifestyle alone, with its thresholds explicitly labeled as illustrative and hypothesis-generating ^[13]. A perspective in Obesity Pillars calls for “adaptive maintenance”: it states that continued medication has the strongest evidence, and lists candidate strategies — monitored dose reduction with predefined re-escalation criteria, oral switching, reduced-frequency dosing, intermittent rescue therapy, and structured lifestyle support — with the aim of finding the minimum effective maintenance intensity for each person. Those strategies still require prospective validation ^[27].

Is there a tested way to taper off?

Not yet. A 2026 review concludes that reduced-intensity maintenance may attenuate regain compared with abrupt discontinuation, but whether structured tapering can actually enable people to come off the drug remains unknown and needs prospective evaluation ^[25].

One trial is designed to answer that. The REST trial (registered as NCT07294950) plans to randomize adults with obesity, without preexisting cardiovascular disease, who have lost at least 10% of their weight on semaglutide and plateaued for 12 weeks, to either a gradual 16-week dose reduction or abrupt discontinuation. The primary outcome is the difference in percent weight change between the groups. This is a published protocol; the results are pending ^[29].

Older evidence points the other way. In the S-LiTE post-treatment study, adults who lost 13.1 kg on an 8-week diet were given a year of supervised exercise, liraglutide 3.0 mg, both, or placebo, then followed for a year off everything. The exercise-plus-liraglutide group ended 5.1 kg lighter than the liraglutide-alone group at week 104, and regain in the year after stopping was 6.0 kg larger after liraglutide alone than after exercise alone ^[26].

The Wegovy label also addresses an unplanned gap: if 2 or more consecutive doses of the injection are missed, the label says to reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions ^[1].

How many people actually stay on these drugs?

Real-world persistence is far short of “forever.” A Prime Therapeutics claims analysis of 33,607 commercially insured members without diabetes found that one-year persistence rose from 33.2% among people who started in 2021 to 60.9% among those who started in the first half of 2024. For semaglutide specifically, one-year persistence by start year was 33.2%, 34.1%, 39.8%, and 58.6%. For tirzepatide, available from 2023, it was 64.0% and 64.8% ^[23].

The authors attribute the improvement to resolution of GLP-1 shortages, better dose escalation and side-effect management, and lifestyle programs, while noting that more research is needed on why people stop and on long-term cost-effectiveness ^[23]. A Danish national cohort study published in JAMA Network Open in 2026 examined the risk of stopping semaglutide and the baseline characteristics that predict it, but no figures from that study appear in the available text ^[22].

What does years of Wegovy cost in the US?

For self-pay patients, NovoCare pricing is $349 per month for the Wegovy pen at every dose from 0.25 mg through 2.4 mg, and $399 per month for the 7.2 mg HD pen. New patients pay $199 per month for their first two fills of the 0.25 mg or 0.5 mg pens, an offer that runs through December 31, 2026. A month is defined as one box of 4 pens. The Wegovy pill is $149 per month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg ^[14][18].

Way to pay	Price	Notes
NovoCare self-pay pen	$349/month	All doses 0.25–2.4 mg; HD 7.2 mg is $399 [14][18]
New-patient pen offer	$199/month	First 2 fills of 0.25 or 0.5 mg, through Dec 31, 2026 [14][18]
NovoCare self-pay pill	$149–$299/month	$149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) [14][18]
Telehealth subscription, pen	$329 / $299 / $249 per month	3-, 6-, and 12-month plans; available from March 31, 2026 [15]
Telehealth subscription, pill (9 or 25 mg)	$289 / $269 / $249 per month	3-, 6-, and 12-month plans [15]
Commercial insurance savings offer	As little as $25/month	Max savings $100/month; government beneficiaries excluded [14][18]

As arithmetic, not a quoted price: $349 per month for 12 months works out to $4,188, and the 12-month subscription pen price of $249 per month works out to $2,988. Those are calculations from the monthly figures, not prices anyone has announced for a year of treatment.

Separately, Novo Nordisk has cut the list price (wholesale acquisition cost) of Wegovy 2.4 mg injection and 25 mg tablets to $675 per month, effective January 1, 2027 — roughly a 50% reduction. The company states this does not affect direct-to-patient self-pay prices, and that the change matters mainly for people whose out-of-pocket costs are tied to list price, such as those with coinsurance or high-deductible plans ^[17].

Does Medicare pay for Wegovy long term?

Medicare is running a short-term demonstration called the Medicare GLP-1 Bridge, from July 1, 2026 through December 31, 2027, that provides eligible Part D beneficiaries access to certain GLP-1 drugs for a $50 copay. The Bridge operates outside the Part D benefit: the Part D deductible does not apply, no part of the $50 counts toward true out-of-pocket (TrOOP) costs, and there is no low-income subsidy for it. A single central processor handles prior authorization, claims, and pharmacy payment. CMS extended the Bridge through December 31, 2027 because the BALANCE model is not launching in 2027 ^[16].

A CVS Caremark release from May 2026 states that Part D beneficiaries may pay $50 per month for Zepbound and Foundayo through the Bridge beginning July 1 ^[20].

What happens if insurance or formulary rules change mid-treatment?

Coverage can shift under people who are already treated. CVS Caremark removed Zepbound from its formulary effective July 1, 2025, making Wegovy the preferred option. Members who had tried Wegovy and had intolerable side effects or insufficient weight loss could request a formulary exception for tirzepatide, and existing Zepbound prior authorizations were transferred to Wegovy so members did not have to repeat the process ^[19].

A Truveta analysis of 700,907 patients found that monthly switching away from tirzepatide rose from about 0.6% before May 2025 to 10.2% in June and July of that year, then leveled off ^[20]. Effective October 1, 2026, CVS Caremark is adding Zepbound back as an additional preferred option, and it removed its new-to-market block on Foundayo effective June 1, 2026. Wegovy’s pen and pill keep preferred status, and eligible commercially insured patients may pay $25 per month ^[20].

Employer plans add their own conditions. In the Business Group on Health’s 2026 survey, 90% of employers covering GLP-1s for obesity required prior authorization, 54% required participation in a weight-management program, and 48% set BMI or comorbidity thresholds beyond the FDA label. Seventy-nine percent reported rising utilization of obesity treatments ^[21].

What is the bottom line on “forever”?

The honest summary of the evidence is this: the label sets no end date ^[1]; professional guidance strongly recommends continuing medication during maintenance ^[3]; and withdrawal trials show that most lost weight returns within a year of stopping ^[4][5]. About four years of randomized safety data exist for semaglutide 2.4 mg from SELECT, and no randomized data beyond that appear in these sources ^[7][8].

At the same time, the labels themselves describe lower maintenance doses for both drugs, oral maintenance has one year of randomized support, and taper trials are pending ^{[1][2][12][29]}. What to take, at what dose, for how long, and whether to try stepping down are decisions for a prescriber who knows the full health picture — and, given the cost and coverage material above, often for an insurer as well.

Sources

1. Novo Nordisk. Wegovy prescribing information.
2. Eli Lilly. Zepbound (tirzepatide) injection, for subcutaneous use: prescribing information.
3. PubMed. Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.
4. JAMA. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
5. PubMed. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
6. eClinicalMedicine. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression.
7. New England Journal of Medicine. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
8. Nature Medicine. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
9. Nature Medicine. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
10. Obesity. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. 2025.
11. The Lancet. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. June 6, 2026.
12. Nature Medicine. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
13. PubMed. From Induction to Maintenance? Rethinking GLP-1-Based Obesity Pharmacotherapy in the Era of Oral Agents.
14. Novo Nordisk. Wegovy price guide.
15. PR Newswire. Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy, offering savings of up to $1,200/year.
16. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
17. PR Newswire. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access.
18. NovoCare. Wegovy (semaglutide) cost, coverage, and savings resources.
19. Massachusetts Group Insurance Commission. CVS Caremark decides to remove Zepbound from CVS Caremark formulary.
20. Managed Healthcare Executive. CVS Caremark to put Zepbound back on formulary and add Foundayo. May 28, 2026.
21. Business Group on Health. 2026 Employer Health Care Strategy Survey: Executive Summary.
22. PubMed. Discontinuation of Semaglutide Therapy for Obesity Management.
23. PubMed. Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.
24. People. Article on Oprah’s experience stopping GLP-1 medications for 12 months.
25. PubMed. Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.
26. PubMed. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.
27. PubMed. Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm.
28. PubMed. From Guidelines to Clinical Practice: Expert Perspectives on Long-Term Management of Obesity.
29. PubMed. Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.